Juvenile Idiopathic Arthritis Market Size is Estimated to Grow at a CAGR of 4.6% Through 2036, Estimates DelveInsight

Source Summary

Emerging Juvenile Idiopathic Arthritis Therapies include Upadacitinib (RINVOQ), Sarilumab (KEVZARA), Deucravacitinib (SOTYKTU), Abatacept (ORENCIA), Bimekizumab (BIMZELX), MAS825, Filgotinib (JYSELECA), and others. DelveInsight's Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast - 2036 report delivers an in-depth understanding of JIA, historical